Chiesi Farmaceutici SpA has patented TGF-β receptor type-1 (ALK5) inhibitors reported to be useful for the treatment of idiopathic pulmonary fibrosis.

Dong Wha Pharmaceutical Co. Ltd. has defined histone-lysine N-methyltransferase EZH1 and/or EZH2 inhibitors reported to be useful for the treatment of cancer.

Constellation Pharmaceuticals Inc. has found three-prime repair exonuclease 1 (TREX1) inhibitors reported to be useful for the treatment of cancer.

Ventyx Biosciences Inc. has identified 15-hydroxyprostaglandin dehydrogenase (15-PGDH) inhibitors reported to be useful for the treatment of ulcerative colitis and pulmonary fibrosis.

The Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has described androgen receptor antagonists and/or androgen receptor degradation inducers reported to be useful for the treatment of gastrointestinal disorders, osteoporosis and SARS-CoV-2 infection (COVID-19), as well as breast and castration-resistant prostate cancer.

BioWorld MedTech presents Patent Highlights, an excerpt of the most important med-tech patents from this week's Cortellis Patent Gazette.

Fudan University and Shanghaitech University have developed proteolysis targeting chimeras (PROTACs) comprising an E3 ubiquitin ligase binding agent coupled to Bcl-2-like protein 1 (Bcl-xl; Bcl-X; BCL2L1) targeting moiety via linker. They are reported to be useful for the treatment of cancer, autoimmune disease, myelofibrosis, neurodegeneration, kidney fibrosis, transplant rejection, diabetes and cardiovascular disorders, among others.

Pyrrole fused-ring pyrazole compounds have been prepared by Hangzhou Zhongmei Huadong Pharmaceutical Co. Ltd. and characterized as mitogen-activated protein kinase kinase kinase kinase 1 (MAP4K1; HPK1; MEKKK1) inhibitors reported to be useful for the treatment of cancer.